

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

11-05-01

LAW OFFICES OF JONATHAN ALAN QUINE

By:

*Liane Brook*

Atty Docket No: 12E-989110US  
Client Ref: G67



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jagdish Parasrampuria; Maxine B. Yonker;  
Kenneth E. Schwartz; Marc J. Gurwith  
Application No.: 09/526802

Filed: 3/16/2000

For: **DHEA Composition And Method**

Examiner: Qazi, S.

Art Unit: 1616

**RESPONSE**

#11098  
1-16-02  
**RECEIVED**  
JAN 14 2002  
TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated October 4, 2001, Applicants respectfully request reconsideration of the above-identified application in view of the following remarks.

**REMARKS**

**Status of the Claims.**

Claims 1-35 are pending in the application

**Election/Restriction.**

In the Office Action, the Examiner restricted the claims under 35 U.S.C. § 121, requiring Applicants to elect one of the following claim groups for prosecution in the present application, stating:

- I. Claims 1-4 are drawn to pharmaceutical formulations of DHEA, classified in class 514, subclass 169+.
- II. Claims 5-10 are drawn to [a] method for preparing formulations, classified in class 514, subclass 169+.
- III. Claims 11-15 are drawn to a method of administering DHEA, treatment of systemic lupus erythematosus, classified in class 514, subclass 169+.